AbbVie (ABBV)
(Delayed Data from NYSE)
$195.45 USD
-1.37 (-0.70%)
Updated Oct 3, 2024 04:00 PM ET
Pre-Market: $195.00 -0.45 (-0.23%) 9:14 AM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$195.45 USD
-1.37 (-0.70%)
Updated Oct 3, 2024 04:00 PM ET
Pre-Market: $195.00 -0.45 (-0.23%) 9:14 AM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
Zacks News
Aligos (ALGS) Stock Down on Hepatitis Drug Development Halt
by Zacks Equity Research
Aligos Therapeutics' (ALGS) phase I study evaluating its chronic hepatitis B candidate, ALG-010133, did not achieve sufficient activity against the disease.
Lilly (LLY) Inks Deal for Multiple Neurologic Indications
by Zacks Equity Research
Eli Lilly (LLY) partners with Entos Pharmaceuticals to expand its pipeline in multiple neurologic indications.
Pharma Stock Roundup: FDA Nod to PFE Booster for Age 12-15, Breakthrough Tag to ABBV Drug
by Kinjel Shah
FDA authorizes Pfizer's (PFE) booster shot for adolescents 12 -15 years of age and grants Breakthrough Therapy tag to AbbVie's (ABBV) lung cancer candidate.
Zacks Investment Ideas feature highlights: AbbVie, Inc. and Pfizer Inc
by Zacks Equity Research
AbbVie, Inc. and Pfizer Inc are highlighted in this investment idea article.
How to Select Stocks During Volatile Market Periods
by Bryan Hayes
How to Select Stocks During Volatile Market Periods
4 Reasons Why You Should Add AbbVie (ABBV) to Your Portfolio
by Zacks Equity Research
AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.
Top Analyst Reports for JPMorgan, Toyota & Netflix
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Toyota Motor Corp. (TM) and Netflix, Inc. (NFLX).
AbbVie (ABBV) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
AbbVie (ABBV) is well positioned to outperform the market, as it exhibits above-average growth in financials.
AbbVie (ABBV) Gets FDA Breakthrough Tag for Lung Cancer Drug
by Zacks Equity Research
AbbVie's (ABBV) Breakthrough Therapy Designation for Teliso-V is based on data from the phase II LUMINOSITY study.
Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how AbbVie (ABBV) and Allakos Inc. (ALLK) have performed compared to their sector so far this year.
AbbVie (ABBV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $135.42, marking a +0.01% move from the previous day.
AbbVie (ABBV) Stock Moves -0.01%: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $134.39, moving -0.01% from the previous trading session.
Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DHS
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $132.05, moving +1.62% from the previous trading session.
Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DHS
Pfizer (PFE) COVID Pill Paxlovid Gets CHMP Support in Europe
by Zacks Equity Research
The CHMP supports the use of Pfizer's (PFE) oral COVID-19 drug, Paxlovid, to treat high-risk patients even though it has not received conditional authorization from the European Commission.
Pharma Stock Roundup: PFE Announces Arena Buyout, LLY Ups 2021 View & More
by Kinjel Shah
Pfizer (PFE) offers to buy Arena Pharmaceuticals. Lilly (LLY) raises 2021 profit and sales outlook.
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $131.78, moving +1.19% from the previous trading session.
AbbVie (ABBV) Rinvoq Gets FDA Nod for Active Psoriatic Arthritis
by Zacks Equity Research
The FDA approves AbbVie's (ABBV) Rinvoq for the treatment of adults with active psoriatic arthritis. This is the second FDA-approved indication for the drug.
Lilly (LLY) Phase III Study in Ulcerative Colitis Meets Goal
by Zacks Equity Research
Eli Lilly's (LLY) mirikizumab meets primary and key secondary endpoints in a phase III maintenance study in ulcerative colitis.
Pfizer (PFE) COVID Pill Maintains Strong Efficacy, Stock Up
by Zacks Equity Research
Pfizer's (PFE) COVID-19 pill maintains a substantial reduction in hospitalizations and deaths observed during interim analysis last month in the final analysis of the study data.
SpringWorks (SWTX) & AbbVie Unite for Multiple Myeloma Drug
by Zacks Equity Research
SpringWorks Therapeutics (SWTX) collaborates with AbbVie (ABBV) to evaluate the combination of nirogacestat with AbbVie's ABBV-383 for relapsed or refractory multiple myeloma.
Aprea (APRE) Reports FDA Removal of Clinical Hold on Study
by Zacks Equity Research
The FDA removes its clinical hold on Aprea Therapeutics' (APRE) clinical study evaluating eprenetapopt combination study in lymphoid malignancies.
Pharma Stock Roundup: PFE Booster Works on Omicron, AZN COVID Cocktail Gets FDA Nod
by Kinjel Shah
Pfizer (PFE) and BioNTech's COVID-19 booster shot proves effective against the Omicron variant. FDA grants EUA to AstraZeneca's (AZN) cocktail antibody for pre-exposure prophylaxis (prevention) of COVID-19.
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $124.15, moving +1.87% from the previous trading session.